These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 22882428)
1. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Khan N; Abbas AM; Bazzano LA; Koleva YN; Krousel-Wood M Aliment Pharmacol Ther; 2012 Oct; 36(8):755-64. PubMed ID: 22882428 [TBL] [Abstract][Full Text] [Related]
2. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. Khan N; Abbas AM; Koleva YN; Bazzano LA Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878 [TBL] [Abstract][Full Text] [Related]
3. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. Bello C; Belaiche J; Louis E; Reenaers C J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881 [TBL] [Abstract][Full Text] [Related]
4. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Khan N; Abbas AM; Lichtenstein GR; Loftus EV; Bazzano LA Gastroenterology; 2013 Nov; 145(5):1007-1015.e3. PubMed ID: 23891975 [TBL] [Abstract][Full Text] [Related]
5. Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. Richter JM; Kushkuley S; Barrett JA; Oster G Aliment Pharmacol Ther; 2012 Aug; 36(3):248-56. PubMed ID: 22690748 [TBL] [Abstract][Full Text] [Related]
6. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Moss AC; Lillis Y; Edwards George JB; Choudhry NK; Berg AH; Cheifetz AS; Horowitz G; Leffler DA Am J Gastroenterol; 2014 Dec; 109(12):1850-5. PubMed ID: 24913040 [TBL] [Abstract][Full Text] [Related]
7. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Frieri G; Pimpo M; Galletti B; Palumbo G; Corrao G; Latella G; Chiaramonte M; Caprilli R Dig Liver Dis; 2005 Feb; 37(2):92-6. PubMed ID: 15733520 [TBL] [Abstract][Full Text] [Related]
8. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance. Elkjaer M Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851 [TBL] [Abstract][Full Text] [Related]
9. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519 [TBL] [Abstract][Full Text] [Related]
10. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Lee HJ; Jung ES; Lee JH; Hong SP; Kim TI; Kim WH; Cheon JH Hepatogastroenterology; 2012; 59(117):1415-20. PubMed ID: 22683958 [TBL] [Abstract][Full Text] [Related]
11. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Gifford AE; Berg AH; Lahiff C; Cheifetz AS; Horowitz G; Moss AC Am J Gastroenterol; 2013 Feb; 108(2):249-55. PubMed ID: 23295279 [TBL] [Abstract][Full Text] [Related]
12. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database. Lachaine J; Yen L; Beauchemin C; Hodgkins P BMC Gastroenterol; 2013 Jan; 13():23. PubMed ID: 23363459 [TBL] [Abstract][Full Text] [Related]
13. Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. Mitra D; Hodgkins P; Yen L; Davis KL; Cohen RD BMC Gastroenterol; 2012 Sep; 12():132. PubMed ID: 23006789 [TBL] [Abstract][Full Text] [Related]
14. An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements. Moshkovska T; Stone MA; Clatworthy J; Smith RM; Bankart J; Baker R; Wang J; Horne R; Mayberry JF Aliment Pharmacol Ther; 2009 Dec; 30(11-12):1118-27. PubMed ID: 19785623 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Garcia-Planella E; Mañosa M; Van Domselaar M; Gordillo J; Zabana Y; Cabré E; López San Román A; Domènech E Dig Liver Dis; 2012 Mar; 44(3):206-10. PubMed ID: 22079262 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Kane SV; Cohen RD; Aikens JE; Hanauer SB Am J Gastroenterol; 2001 Oct; 96(10):2929-33. PubMed ID: 11693328 [TBL] [Abstract][Full Text] [Related]
17. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Rowe FA; Walker JH; Karp LC; Vasiliauskas EA; Plevy SE; Targan SR Am J Gastroenterol; 2000 Aug; 95(8):2000-8. PubMed ID: 10950049 [TBL] [Abstract][Full Text] [Related]
18. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Kane S; Becker B; Harmsen WS; Kurian A; Morisky DE; Zinsmeister AR Am J Gastroenterol; 2012 Feb; 107(2):154-60. PubMed ID: 22306937 [TBL] [Abstract][Full Text] [Related]
19. Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. Hodgkins P; Swinburn P; Solomon D; Yen L; Dewilde S; Lloyd A Patient; 2012; 5(1):33-44. PubMed ID: 22077619 [TBL] [Abstract][Full Text] [Related]